Ownership and insider activity for Intensity Therapeutics, Inc. (INTS): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials.
Price
| Price | $3.83 |
| Market Cap | $10M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-16 | DUBIN THOMAS I H | A-Award | 5,500 | $27K |
| 2026-07-16 | Donovan Daniel | A-Award | 5,500 | $27K |
| 2026-07-16 | GOLDBERG MARK A | A-Award | 5,500 | $27K |
| 2026-07-16 | Leahy Emer | A-Award | 5,500 | $27K |
| 2026-07-16 | Wesolowski John M | A-Award | 11,000 | $54K |
| 2026-07-16 | Talamo Joseph | A-Award | 34,000 | $167K |
| 2026-07-16 | BENDER LEWIS H | A-Award | 78,000 | $382K |
| 2026-06-30 | Wesolowski John M | A-Award | 3,688 | $13K |
| 2026-06-30 | Talamo Joseph | A-Award | 1,093 | $4K |
| 2026-03-26 | BENDER LEWIS H | A-Award | 37,749 | $231K |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.8M | $9.3M | $4.5M | $1.3M | $8.6M | $2.6M | $11.9M |
| Short-term Investments | $4.6M | 0 | 0 | 0 | $6.2M | 0 | 0 |
| Receivables | $33634 | $48521 | $51262 | $62304 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $8.6M | $9.5M | $4.7M | $1.5M | $15.5M | $3.4M | $12.7M |
| Property, Plant & Equipment | $252668 | $490240 | $318126 | $139000 | $147000 | $122000 | $96000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $9.0M | $10.1M | $5.2M | $1.8M | $17.3M | $4.8M | $14.1M |
| Accounts Payable | $393963 | $222707 | $172508 | $603000 | $3.0M | $1.2M | $583000 |
| Short-term Debt | $117194 | 0 | $2.0M | $4.3M | 0 | 0 | 0 |
| Total Current Liabilities | $1.1M | $1.3M | $3.7M | $6.8M | $4.0M | $1.8M | $2.1M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | $79000 |
| Total Liabilities | $1.3M | $11.7M | $13.9M | $16.9M | $4.1M | $1.9M | $2.2M |
| Retained Earnings | 0 | -$23.2M | -$31.1M | -$38.7M | -$50.5M | -$66.8M | -$78.4M |
| Total Equity | $7.7M | -$1.6M | -$8.7M | -$15.1M | $13.2M | $2.9M | $11.9M |
| Total Debt | $260270 | $497481 | $2.3M | $4.5M | $158000 | $138000 | $110000 |
| Net Debt | -$8.1M | -$8.8M | -$2.2M | $3.2M | -$14.6M | -$2.5M | -$11.8M |
| Working Capital | $7.5M | $8.1M | $1.0M | -$5.4M | $11.5M | $1.6M | $10.6M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 5.00 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 27.84 |
Profitability
| Return on Equity | -97.73% |
| Return on Invested Capital | -99.88% |
| Return on Assets | -82.31% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ANTX · BOLD · IBIO · ITRM · NXTC · PLUR · PSTV
Explore sector: Healthcare · Biotechnology
More sections of INTS: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks